Twist Bioscience Co. (NASDAQ:TWST) Director Sells $250,000.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the transaction, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $43.60 on Friday. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The business has a fifty day moving average of $46.35 and a two-hundred day moving average of $46.46. The stock has a market cap of $2.59 billion, a PE ratio of -12.11 and a beta of 1.85.

Analysts Set New Price Targets

Several research firms have recently issued reports on TWST. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research initiated coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Finally, Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in shares of Twist Bioscience by 4,133.1% in the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after acquiring an additional 300,891 shares in the last quarter. Arizona State Retirement System boosted its stake in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after purchasing an additional 308 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Twist Bioscience by 16.7% during the second quarter. Los Angeles Capital Management LLC now owns 10,304 shares of the company’s stock worth $508,000 after purchasing an additional 1,475 shares during the last quarter. Caprock Group LLC increased its stake in shares of Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after buying an additional 220 shares in the last quarter. Finally, Headlands Technologies LLC raised its holdings in shares of Twist Bioscience by 38.9% in the second quarter. Headlands Technologies LLC now owns 5,018 shares of the company’s stock valued at $247,000 after buying an additional 1,405 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.